Ipsen has announced the opening of a brand new “cutting-edge” research and development centre within Ipsen BioInnovation, based at Milton Park in Oxfordshire.
The new laboratory will specialise in neuroscience research, helping tackle disorders of the brain, spinal cord or nerves but with wider capabilities to investigate medicines in oncology and rare diseases as well.
Employing over 80 local people, including 40 research scientists, Ipsen’s site at Milton Park is already a “global hub for innovation”, and the new research centre is part of a continuum of investment, which now exceeds £12 million within the last year.
John Chaddock, VP neurology, site head at Ipsen BioInovation said that he is “extremely proud” of the team team of “highly skilled scientists and researchers who oversee industry-leading work in the field of neuroscience at Milton Park.”
He continued, “Within the last four years Ipsen has invested over £150million across our three UK sites, the majority being to enhance our R&D and manufacturing capabilities. Through this continued development of our research facilities at Milton Park, we are working relentlessly in the discovery and development of new compounds designed to treat disease and improve quality of life for patients.”
The centre will enable scientists to “better support the development of current and future biological medicines.”